Research Revolutionizing Patient Care and Treatment Strategies

Our study found that a composite mortality variable leveraging multiple data sources yields high validity when compared against the gold-standard NDI. Given evidence highlighting the challenges of mortality data documentation in the real-world setting, the use of a composite mortality variable can provide significant benefits in quality of documentation and research results.

Overall, our data help to better understand the rapidly evolving treatment paradigm for ≥2L CLL in the rw setting. Although there has been steady uptake of targeted therapies across LOTs, unmet need persists for patients with CLL/SLL who receive later LOTs. Our study demonstrates deterioration in outcomes, including rwPFS and rwOS, as patients advance to later LOTs, even after the approvals of targeted therapies, and highlights the meaningful proportion of patients who discontinue targeted agents because of toxicity. As such, our data highlight the persistent unmet need for new and effective treatment options to improve health outcomes for patients with CLL who have received ≥2L LOTs.

Contrary to our expectations of finding significant cancer care disparities, we did not observe any differences in molecular tumor testing rates, time to initiation of therapy, or short-term survival by treatment site or race/ethnicity status. Our results suggest that integrated, specialized, guideline-concordant care in comprehensive cancer centers has the potential to eliminate CRC outcome disparities among pts diagnosed at these centers.